Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Preceptorship on Lung Cancer and Other Thoracic Malignancies 2022: Paris
- Start date
- 17 Nov 2022
- End date
- 18 Nov 2022
- Location
- Paris, France
Learning objectives
- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma
Accreditation
The programme of this event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Fabrice Barlesi, France
- Solange Peters, Switzerland
- David Planchard, France
Supported by
